12/3
08:44 am
erna
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models [Yahoo! Finance]
Medium
Report
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models [Yahoo! Finance]
12/3
08:30 am
erna
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
Medium
Report
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
11/25
08:37 am
erna
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program [Yahoo! Finance]
Medium
Report
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program [Yahoo! Finance]
11/25
08:30 am
erna
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Medium
Report
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
11/14
08:42 am
erna
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing [Yahoo! Finance]
Low
Report
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing [Yahoo! Finance]
11/14
08:30 am
erna
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
Medium
Report
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
10/30
08:30 am
erna
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
Medium
Report
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
10/17
08:22 am
erna
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases [Yahoo! Finance]
High
Report
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases [Yahoo! Finance]
10/17
08:00 am
erna
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
Medium
Report
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases